BETA-ADRENERGIC blocking agents have been used with success in angina pectoris (Alleyne et al, 1963; Hamer et al, 1964; Keelan, 1965) ; and in various cardiac arrthymias (Besterman and Friedlander, 1965) . Snow (1965) administered 10-20 mg. of propranolol (Inderal-I.C.I.) eight-hourly to 45 patients with myocardial infarction and found that the mortality in the treated cases was 16 per cent. compared with 35 per cent. in the controls. Snow's results have been challenged by Balcon et al (1966) and by Clausen et al (1966) .
Agents of this type can reduce the cardiac output and may therefore predispose to heart failure. It was felt that this risk was acceptable if they would prolong the survival time after acute myocardial infarction.
PLAN OF TRIAL
Earlier work had suggested that about 30 per cent. of patients treated in hospital for acute myocardial infarction died within 4 weeks, most of these within the first few days. It was decided that if the administration of propranolol reduced this death rate to 15 per cent. it would be of clinical value. Consequently the trial was designed to have a 95 per cent. probability of detecting, at the conventional 5 per cent. probability level of significance, a critical difference of 15 per cent. in the survival rate at 4 weeks after onset of a group of patients on propranolol and a control group.
Patients were admitted to the trial if they had a clinical history of myocardial infarction within the preceding 24 hours and electrocardiographic changes compatible with this diagnosis. Serum glutamic oxalacetic transaminase (S.G.O.T.) levels were estimated but no patient was admitted to the trial on this criterion alone. Patients who had been admitted on clinical grounds and in whom subsequent cardiographs failed to reveal the expected changes were withdrawn from the trial.
No patient with a heart rate of under 60 beats per minute was admitted to the trial, whether this was due to sinus bradycardia or atrio-ventricular block. Asthma or broncho-spasm was also regarded as a contra-indication, as was a systolic blood pressure less than 90 mm. Hg. They were all electrocardiographically monitored in the first 48 hours at least. Propranolol was given in the dose of 40 mgms. sixhourly for 28 days. This is a larger dose than those used by Snow (1965 ), Balcon et al (1966 and Clausen et al (1966) . Particular attention was directed to the development of heart failure, rhythm changes and further episodes of cardiac pain. This is a restricted sequential trial with the valuation of treatments by observed preferences between patients within pairs, each member of a pair being differently treated. The design was described by Armitage (1960) . Treatments were allotted at random to each pair; preferences are defined as pairs in which one patient was successfully treated. The criterion of success was survival at 4 weeks. In Armitage's (1960) notation the specific sequential plan required to satisfy the conditions is identified by the specification given in Fig. 1 .
Each patient was allotted to one of four sub-groups according to age, under 60 years, 60 years and over, and sex. Within each of two hospitals and within each of the sub-groups patients were allotted to two treatment groups at random in accordance with a previously prepared plan. RESULTS In all, 107 patients were admitted to the trial during the period December, 1965 September, 1966 . Of these, 8 were withdrawn from the trial as they did not meet the above criteria, 2 were on propranolol and 6 on the placebo. This left 42 pairs of patients and of these only 12 yielded preferences, of which 7 were for propranolol. These preferences are plotted on indicating non-significance was crossed it was estimated that the patients would have to be admitted to the trial for the next six years. (21) - (4) 20.0 (10) Placebo - ( 11) 26.1 (23) - (2) 54.5 (11) Number of patients in each sub-group is given in brackets.
In view of the apparent similarity of the effects of the two treatments, it was decided to terminate the sequential trial and compare the death rates between treatment regimes by convential x2 tests or exact probability tests. The 99 patients who completed the trial were included in this analysis. Table I shows that there was no significant difference (at P<0.05) between the mortality of patients on propranolol and those on the placebo. Table II shows the mortality rates in each treatment regime within each of the four age-sex sub-groups. The number of patients of either sex in the younger age group was too few to permit a comparison of mortality to be made. In the older age group, no significant difference was found in the mortality for either males (X2=0.036, D.F.= I, 0.9>P>0.8), or females (P, double tail=0.183).
COMPLICATIONS
No serious side effects were encountered during this trial. Eighteen cases developed heart failure in the control group, as against twenty on propranolol. There was no evidence that this procedure precipitated heart failure in any case. In two patients on propranolol the systolic blood pressure fell to 80. After the omission of one dose the pressure rose within a few hours and remained satisfactory. Table III shows the percentage number of patients with heart failure, rhythm change, and further attacks of heart pain for each treatment regime. The arrythmias encountered included multiple ectopic beats, auricular tachycardia, auricular fibrillation, ventricular tachycardia, and ventricular fibrillation. No significant difference was found in percentage incidence for any particular complication (see X2's of Table 3 ). Similar trends were found when the incidences were compared within each age and sex sub-group. SUMMARY In a trial of propranolol (40 mgms. six-hourly) in patients with acute myocardial infarction, no significant difference in mortality at 4 weeks was demonstrated between the drug and the placebo. The incidence of heart failure, cardiac arrythmias, and further episodes of cardiac pain was similar in both groups.
